Vertex Pharmaceuticals v. Lupin — Generic Kalydeco Formulation Does Not Infringe Narrow 80% Ivacaftor Claims
A Delaware federal court held that Lupin’s roughly 74% ivacaftor generic does not infringe Vertex patent claims requiring 80% or about 80% ivacaftor.